Trial · NCT06299813
Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection
NCT06299813, Phase 3, Unknown, A.O.U. Città della Salute e della Scienza
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection. Trials, record NCT06299813. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06299813
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection
- NCT number
- NCT06299813
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 80 participants, estimated
- Lead sponsor
- A.O.U. Città della Salute e della Scienza
- Conditions
- Adenovirus
- Interventions
- Bentelan, Placebo
- First posted
- 2024-03-08
- Last updated
- 2024-03-21
- Other registries' IDs
- eudract:2022-002955-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with a sustained fever resolution at 24 hours from randomization | at 18 and 24 hours from randomization | The proportion of patients achieving sustained fever resolution at 24 hours from is the proportion of patients with a a body temperature \<37.5°C at 18 and 24 hours from randomization. |
| Secondary | Pharyngeal-tonsillar pain level in patients younger than 36 months | from the date of randomization, up to 72 hours | According to the patient age, the pharyngeal-tonsillar pain level of the child will be measured by the FLACC (Face, Legs, Activity, Cry, Consolability) scale in patients younger than 36 months. FLACC mean value 5 points on ten. |
| Secondary | Hospitalization | from date of randomization until the date of discharge from emergency department, up to 72 hours | The proportion of patients admitted following emergency access. |
| Secondary | Duration of hospitalization (among those hospitalized), measured in days | from date of randomization until the date of discharge,up to 72 hours | Number of days from admission date to discharge date. |
| Secondary | Cumulative incidence of fever resolution | from date of randomization to 72 hours from randomization | Cumulative incidence of fever resolution is measured from randomization until the fever resolution confirmed by measurement at the subsequent timepoint; patients without fever resolution within the time of the last fever assessment are censored at this time. |
| Secondary | Fever duration | from date of randomization until 72 hours from randomization | Time from randomization until the first measurement with Body Temperature\<37.5°C |
| Secondary | Pharyngeal-tonsillar pain level in patients older than 36 months | from the date of randomization, up to 72 hours | According to the patient's age, the pharyngeal-tonsillar pain level of the child was measured by the Faces Pain Rating Scale (Wong-Baker Scale) in patients with age more or equal to 36 months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06299813
GET https://conductscience.org/api/trials/v1/NCT06299813/registered